402 related articles for article (PubMed ID: 28322415)
1. Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock.
Vail E; Gershengorn HB; Hua M; Walkey AJ; Rubenfeld G; Wunsch H
JAMA; 2017 Apr; 317(14):1433-1442. PubMed ID: 28322415
[TBL] [Abstract][Full Text] [Related]
2. Norepinephrine Shortage Led to Increased Deaths from Septic Shock.
Stockwell S
Am J Nurs; 2017 Jul; 117(7):15. PubMed ID: 28644271
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Practice Changes in the Care of Patients with Septic Shock during the U.S. Norepinephrine Shortage.
Wunsch H; Hua M; Walkey AJ; Rubenfeld G; Vail E; Gershengorn HB
Ann Am Thorac Soc; 2018 Apr; 15(4):509-511. PubMed ID: 29537858
[No Abstract] [Full Text] [Related]
4. Epidemiology of Vasopressin Use for Adults with Septic Shock.
Vail EA; Gershengorn HB; Hua M; Walkey AJ; Wunsch H
Ann Am Thorac Soc; 2016 Oct; 13(10):1760-1767. PubMed ID: 27404213
[TBL] [Abstract][Full Text] [Related]
5. Practice Patterns and Outcomes Associated With Choice of Initial Vasopressor Therapy for Septic Shock.
Fawzy A; Evans SR; Walkey AJ
Crit Care Med; 2015 Oct; 43(10):2141-6. PubMed ID: 26079345
[TBL] [Abstract][Full Text] [Related]
6. Effect of norepinephrine on the outcome of septic shock.
Martin C; Viviand X; Leone M; Thirion X
Crit Care Med; 2000 Aug; 28(8):2758-65. PubMed ID: 10966247
[TBL] [Abstract][Full Text] [Related]
7. Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study).
Póvoa PR; Carneiro AH; Ribeiro OS; Pereira AC;
Crit Care Med; 2009 Feb; 37(2):410-6. PubMed ID: 19114885
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock.
Roberts RJ; Miano TA; Hammond DA; Patel GP; Chen JT; Phillips KM; Lopez N; Kashani K; Qadir N; Cairns CB; Mathews K; Park P; Khan A; Gilmore JF; Brown ART; Tsuei B; Handzel M; Chang AL; Duggal A; Lanspa M; Herbert JT; Martinez A; Tonna J; Ammar MA; Nazer LH; Heavner M; Pender E; Chambers L; Kenes MT; Kaufman D; Downey A; Brown B; Chaykosky D; Wolff A; Smith M; Nault K; Gong MN; Sevransky JE; Lat I;
Crit Care Med; 2020 Oct; 48(10):1445-1453. PubMed ID: 32706559
[TBL] [Abstract][Full Text] [Related]
9. A time-sensitive analysis of the prognostic utility of vasopressor dose in septic shock.
Chotalia M; Matthews T; Arunkumar S; Bangash MN; Parekh D; Patel JM
Anaesthesia; 2021 Oct; 76(10):1358-1366. PubMed ID: 33687732
[TBL] [Abstract][Full Text] [Related]
10. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
Avni T; Lador A; Lev S; Leibovici L; Paul M; Grossman A
PLoS One; 2015; 10(8):e0129305. PubMed ID: 26237037
[TBL] [Abstract][Full Text] [Related]
11. First-Line Vasopressor Use in Septic Shock and Route of Administration: An Epidemiologic Study.
Teja B; Bosch NA; Wijeysundera DN; Wijeysundera HC; Saskin R; Hill AD; Stelfox HT; Walkey AJ; Wunsch H
Ann Am Thorac Soc; 2022 Oct; 19(10):1713-1721. PubMed ID: 35709214
[No Abstract] [Full Text] [Related]
12. Association Between Hospital Case Volume of Sepsis, Adherence to Evidence-Based Processes of Care and Patient Outcomes.
Fawzy A; Walkey AJ
Crit Care Med; 2017 Jun; 45(6):980-988. PubMed ID: 28350646
[TBL] [Abstract][Full Text] [Related]
13. Continuation of Statin Therapy and Vasopressor Use in Septic Shock.
Zechmeister C; Hurren J; McNorton K
Ann Pharmacother; 2015 Jul; 49(7):790-5. PubMed ID: 25896127
[TBL] [Abstract][Full Text] [Related]
14. Addition of vasopressin to norepinephrine as independent predictor of mortality in patients with refractory septic shock: an observational study.
Micek ST; Shah P; Hollands JM; Shah RA; Shannon WD; Kollef MH
Surg Infect (Larchmt); 2007 Apr; 8(2):189-200. PubMed ID: 17437364
[TBL] [Abstract][Full Text] [Related]
15. Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series Analysis.
Bauer SR; Sacha GL; Reddy AJ
Ann Pharmacother; 2020 Apr; 54(4):314-321. PubMed ID: 31679395
[No Abstract] [Full Text] [Related]
16. Practice Patterns in the Initiation of Secondary Vasopressors and Adjunctive Corticosteroids during Septic Shock in the United States.
Bosch NA; Teja B; Wunsch H; Walkey AJ
Ann Am Thorac Soc; 2021 Dec; 18(12):2049-2057. PubMed ID: 33975530
[No Abstract] [Full Text] [Related]
17. Combination of norepinephrine with phenylephrine versus norepinephrine with vasopressin in critically ill patients with septic shock: A retrospective study.
Arishi H; AlQahtani S; Tamim H; Sadat M; Alenezi FZ; Bin Humaid F; AlWehaibi W; Arabi YM
J Crit Care; 2022 Dec; 72():154121. PubMed ID: 35908329
[TBL] [Abstract][Full Text] [Related]
18. Mortality trends in U.S. adults with septic shock, 2005-2011: a serial cross-sectional analysis of nationally-representative data.
Goto T; Yoshida K; Tsugawa Y; Filbin MR; Camargo CA; Hasegawa K
BMC Infect Dis; 2016 Jun; 16():294. PubMed ID: 27301657
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Second Vasoactive Agents in Septic Shock Refractory to Norepinephrine.
Nguyen HB; Lu S; Possagnoli I; Stokes P
J Intensive Care Med; 2017 Aug; 32(7):451-459. PubMed ID: 27189952
[TBL] [Abstract][Full Text] [Related]
20. Comparison of equipressor doses of norepinephrine, epinephrine, and phenylephrine on septic myocardial dysfunction.
Ducrocq N; Kimmoun A; Furmaniuk A; Hekalo Z; Maskali F; Poussier S; Marie PY; Levy B
Anesthesiology; 2012 May; 116(5):1083-91. PubMed ID: 22407285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
